|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||24.93 - 25.61|
|52 Week Range||12.76 - 26.37|
|PE Ratio (TTM)||215.56|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.18|
Jim Cramer rattled off his take on callers' favorite stocks, including one that was plagued by an activist investor.
The nation's largest independent specialty pharmacy is dispensing CABOMETYX® (cabozantinib) tablets, now with an expanded indication to include first-line therapy for patients with advanced renal cell ...
Zacks.com highlights: Rice Midstream Partners, Jacobs Engineering Group, Lam Research, Diplomat Pharmacy and Forward Air
Since huge debt tends to shoot up the company's risk of bankruptcy, the crux of safe investment lies in identifying low leverage stocks.
FLINT, Mich., Jan. 5, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO) ("Diplomat" or the "Company") today announced that Jeff Park, a member of the Diplomat Board of Directors, has been appointed Interim Chief Executive Officer, effective immediately. Mr. Park's appointment follows the retirement of Phil Hagerman, co-founder of Diplomat in 1975 and Chief Executive Officer and Chairman of Diplomat since 1991.
The nation's largest independent provider of specialty pharmacy services announces reaffirmed guidance for 2017 and preliminary 2018 projections. FLINT, Mich., Jan. 5, 2018 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO) has reaffirmed guidance for the full-year 2017 and provided a preliminary 2018 outlook. This excludes any incremental contribution of LDI (as defined below) for the post-close period in 2017, which was not included in our previous guidance.
Diplomat Pharmacy (DPLO) can be a harbinger of out performance and a signal for a strong earnings profile on the back of its favorable Zacks rank and earnings ESP in the positive territory.
The nation's largest independent provider of specialty pharmacy services closes deal to acquire pharmacy benefit manager and announces new $800 million senior secured credit facilities. FLINT, Mich. , ...
FLINT, Mich. , Dec. 20, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO), has announced that Phil Hagerman , CEO and chairman, and Atul Kavthekar , CFO, will present at the upcoming 36 th Annual ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Diplomat Pharmacy, Inc. Here are 5 ETFs with the largest exposure to DPLO-US. Comparing the performance and risk of Diplomat Pharmacy, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Diplomat Pharmacy, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Diplomat Pharmacy, Inc. – McKesson Corporation, Cardinal Health, Inc., AmerisourceBergen Corporation and Aceto Corporation (MCK-US, CAH-US, ABC-US and ACET-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)
A Relative Strength Rating upgrade for Diplomat Pharmacy shows improving technical performance.
FLINT, Mich., Dec. 11, 2017 /PRNewswire/ -- Diplomat Pharmacy, Inc. (DPLO), has hired Chris Luthin to serve its pharmacy benefit manager (PBM) arm as executive vice president of finance, pharmacy benefit management, and integration. The company announced agreements in November to acquire two PBMs: National Pharmaceutical Services and LDI Integrated Pharmacy Services.
SAN DIEGO, Dec. 11, 2017-- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain purchasers of NYSE: DPLO shares against Diplomat Pharmacy over alleged Violations of Securities ...
NEW YORK, Dec. 05, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
Diplomat Pharmacy shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Rating Action: Moody's assigns B1 CFR to Diplomat Pharmacy; stable outlook. Global Credit Research- 28 Nov 2017. New York, November 28, 2017-- Moody's Investors Service assigned a B1 Corporate Family Rating ...